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As a response to a low quality of reporting of medical research, guidelines for several different types of study design have been
developed to secure accurate reporting and transparency for reviewers and readers from the scientific community.Herein, we review
and discuss the six most widely accepted and used guidelines: PRISMA, CONSORT, STROBE, MOOSE, STARD, and SPIRIT. It is
concluded that the implementation of these guidelines has led to only a moderate improvement in the quality of the reporting of
medical research. There is still much work to be done to achieve accurate and transparent reporting of medical research findings.
1. Introduction
According to the GRADE (Grading of Recommendations
Assessment, Development and Evaluation) methodology,
study designs in medical research can be hierarchically
grouped based on their level of evidence and their strength
of recommendation of clinical interventions (Table 1) [1].
According to this hierarchy, systematic reviews and meta-
analyses of randomized controlled trials (RCTs) rank first
followed by individual RCTs. Below in the hierarchy are
nonrandomized trials and observational study designs such
as cohort studies and case-control studies, whereas case
studies and expert opinions, the so-called anecdotal evidence,
are ranked at the bottom, although they might still have high
impact on clinical decision-making.
Well-designed studies are, however, not sufficient to
ensure transparency inmedical research. It is the presentation
of evidence that is of great importance in the published
scientific article. Notably, to be able to judge the merit and
potential impact of a scientific study reported in a journal
article, the reader must know exactly how the study was done
and what was found. It is essential to easily appraise whether
or not the accomplished research is to have any influence on
healthcare. Researchers use articles as guidance on how to
elaborate a trial and to see if their results have any effect on
their own research. Clinicians use scientific articles to make
out the best treatment of a patient, and finally, government
healthcare providers and public stakeholders utilize them to
guide overall preventive and treatment strategies.
In order to ensure this transparency and accuracy
of reporting medical research, several guidelines have
been gradually introduced [2–4]. Currently, the EQUA-
TOR (Enhancing the QUAlity and Transparency Of health
Research) network [5] has registered 256 guidelines pertain-
ing to various topics within medical research. However, as
early as in 1938, a textbookwas publishedwith a chapter about
howmedical research should be published [6]. Of note, it was
stated that the importance of reporting the results correctly
was not only for the very critical readers’ satisfaction, but
also for the sake of keeping the value in the results [6]. In
1988, the International Committee ofMedical Journal Editors
included a statement in their guidelines to authors stating that
the statistical methods should be described so thoroughly
that a reviewer could verify the results reported [2]. In 1994,
the first attempt to create a reporting guideline was made,
which eventually laid the groundwork for the development of
the Consolidated Standards of Reporting Trials (CONSORT)
statement in 1996 [2].
Herein, we review the six most widely used guidelines for
reporting medical research findings (PRISMA, CONSORT,
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Table 1: Hierarchy of evidence.
Study type Level of evidence Strength of recommendation
Systematic reviews and meta-analyses of randomized controlled trials 1a A
Randomized controlled trials 1b
Nonrandomized controlled trials 2a B
Cohort studies 2b
Case-control studies 3 C
Case studies, expert opinions 4 D
Diagnostic studies — —
STROBE, MOOSE, STARD, and SPIRIT; see meaning of
abbreviations below, Table 2) and investigate how well they
are applied in the medical literature. Furthermore, we clarify
the advantages and disadvantages of using guidelines for
reporting medical research findings.
2. Description of the Specific Guidelines
2.1. PRISMA (http://www.prisma-statement.org/). PRISMA
(Preferred Reporting Items for Systematic Reviews andMeta-
analyses) is developed for the reporting of systematic reviews
and meta-analyses [7]. In 1987, two independent studies
of adequacy in reporting of systematic reviews and meta-
analyses found that reporting was generally insufficient and
did not fulfill the anticipated criteria [8, 9]. In 1996, an
update to one of the studies was made, and no significant
improvement was found, which led to the formulation of
the QUOROM (QUality Of Reporting Of Meta-analyses)
statement [10]. QUOROM was updated to PRISMA in 2005
due to the fact that there had been some changes in the
science of systematic reviews concerning conceptual and
practical advances. In the process of updating the guideline,
it also aimed to improve the consistency throughout the
systematic review report. Scientific authors, methodologists,
medical editors, clinicians, and a consumer participated in
the update.
The PRISMA statement consists of a checklist of 27 items,
which are divided into the following categories: title, abstract,
introduction, methods, results, discussion, and funding. The
PRISMA statement also endorses the use of a flow diagram.
The aim of this statement is to increase transparency and
to improve the reporting of systematic reviews and meta-
analyses. Furthermore, the statement is useful when critically
appraising published systematic reviews.
In 2013, only about 30% of medical journals recom-
mended the PRISMA statement to their authors [11]. In the
same year, an examination of systematic reviews from 2012
showed that articles published in journals that endorsed
PRISMA included, on average, 90.1% of the items, whereas
85.3% of the items were present in articles from journals that
did not endorse the PRISMA statement [11]. In particular,
there was a significantly higher rate of adherence to item
number 17 (“study selection”) of PRISMA (100.0% versus
63.3%). Furthermore, there was an increase from 83.1% to
90.1% in reported items from before the creation of the
statement until 2012 [11]. The study also showed that there
had been a significant increase in methodological quality of
published studies after the introduction of PRISMA.
2.2. CONSORT (http://www.consort-statement.org/). CON-
SORT (Consolidated Standards of Reporting Trials) is a
guideline for reporting randomized controlled trials, of
which the latest version is from 2010 [3].The first CONSORT
statement was developed in 1996 as empirical evidence
implied that authors reported trials badly due to the possible
association with bias [12]. In 2001, a revision was made,
followed by a second revision in 2010, which was based
on accumulated experience. Empirical evidence to support
the statement is located in a database, which is generated
on the basis of more than 700 studies [3]. The CON-
SORT workgroup that keeps the item checklist up to date
consists of biomedical editors, clinical trialists, statisticians,
and epidemiologists. With this constellation, the CONSORT
executive strives to make a balance between established and
emerging researchers.
The CONSORT consists of a 25-item checklist and is
divided into subcategories: title and abstract, introduction,
methods, results, discussion, and other information. This
structure is intended to promote complete reporting and
transparent research. Indirectly, this structure also influences
trial design, conduction, and publication of the trial. This is
the foremost aim of the structure, as it will prevent inade-
quately designed trials from being published. Furthermore,
CONSORT consists of a flow diagram, which enables the
acquirement of a general view of the phases that patients in
the trial go through [2].
When the edited version of CONSORT was published,
more than 400 journals supported the CONSORT statement
[3]. CONSORT is not made to be followed rigidly, which
leaves room to abide by the traditions in the specific research
field, journal style, editorial directions, and also, whenever
possible, the authors’ preferences. It has been stated that the
quality of reporting trials has improved [13]. Particularly, a
study conducted two years after the development of CON-
SORT showed an improvement in the reporting attributable
to the statement [14]. The study compared randomized
controlled trials published before CONSORT (1994) and after
CONSORT (1998). The study was conducted in a way where
the items from the checklist were modified and expanded
so that multiple items were listed as separate, which led
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to 40 items. The improvement was seen in the reporting
of items from 23.4 before CONSORT with a mean change
of 3.7, whereas a decrease of 22% was seen for how often
unclear reporting of allocation concealment took place. This
mean change in the reporting of items from the checklist
is, as mentioned above, still not adequate, when keeping in
mind that, to fulfill all the criteria and secure transparency,
authors should report all 40 items. However, it is important to
remember that the study was conducted only two years after
the implementation of the guideline.
2.3. STROBE (http://www.strobe-statement.org/). STROBE
(STrengthening the Reporting of OBservational studies in
Epidemiology) was developed in 2004 [15]. It is used as
a guideline for reporting observational studies, specifically
cohort, case-control, and cross-sectional studies. The guide-
line arose from the aspiration that this type of research should
be transparently reported to allow the reader to follow what
was planned, done, and found and which conclusions were
drawn. In a series of examinations, it was found that the
reporting of these topics was insufficient for observational
studies [16, 17]. It was discovered that the specification of
potentially confounding variables often was missing, which
was the same case for the explanation of how, for example,
a control and case group were selected. A further aim
was to provide guidance on how observational research
could be reported accurately. The inspiration for STROBE
stemmed from the CONSORT statement, and a group of
methodologists, epidemiologists, statisticians, practitioners,
and journal editors developed the STROBE statement.
The STROBE statement consists of a 22-item checklist
under the following headings: title and abstract, introduction,
methods, results, discussion, and other information. 18 of the
items are identical for the three types of studies, while four
items differ. As for CONSORT, the guideline is not meant
to be followed strictly, and the presentation of information
should depend on the journal style, the authors’ preferences,
and the traditions in the research area.
STREGA (STrengthening the REporting of Genetic Asso-
ciation studies) is an extension to STROBE [18]. Whereas
STROBE is used for observational studies (analytical epi-
demiology), STREGA is used for genetic association studies.
It is the hope that extensions are made to STROBE to cover
other specific topic areas as well.
2.4. MOOSE (http://www.consort-statement.org/downloads).
MOOSE (Meta-analysis Of Observational Studies in Epi-
demiology) is a guideline used for reporting meta-analyses
of observational studies [19]. In 1997, a workshop was held
to design a guideline to improve the usefulness of epidemi-
ological meta-analyses. It was discovered that an increasing
diversity and variability existed in the reporting of these
meta-analyses. The result was a 35-item checklist with the
following headings: background, search strategy, methods,
results, discussion, and conclusion. The aim of this guideline
was to improve the usefulness of epidemiological meta-
analyses by showing more clearly what was done, who did it,
and why it was done in order to help researchers reach this
goal.
2.5. STARD (http://www.stard-statement.org/). STARD (STAn-
dards for the Reporting of Diagnostic accuracy studies) is
intended for reporting studies of diagnostic or prognostic
accuracy [4]. A number of articles in four medical journals
between 1978 and 1993 laid the foundations for a survey of
studies of diagnostic accuracy that showed that the method-
ological quality was poor or at best mediocre. The results
of these studies turned out to be hard to evaluate because
key elements of design, conduct, and analysis were missing
in the majority. It was shown, when compared with other
studies, that specific design features were associated with
biased estimates of diagnostic accuracy [20]. Consequently, a
group was assembled in 1999 to discuss these low standards.
The intention of the group was to create a guideline inspired
by CONSORT, with the goal of improving the quality in
reporting of studies of diagnostic accuracy. The group stated
that the detection of potential biases would be increased
with complete and accurate reporting combined with the
possibility of generalizing and applying the results to other
cases. Finally, the checklist concluded on 25 items under the
following headlines: title/abstract/keywords, introduction,
methods, results, and discussion. A flow diagram adds to the
checklist bringing information about the method used for
patient recruitment and information about inwhich order the
tests had been carried out.
In 2008, a review based on two different studies, which
evaluated the quality of reporting after STARD’s develop-
ment, concluded that the intended effect of STARD was not
yet achieved [21].The review offered a number of suggestions
as to why this was the case. One suggestion was a slow
adoption rate in the medical journals, which was in line with
what other studies have concluded [22]. A second suggestion
was the way the journals described how the authors should
apply the guideline. This varied greatly between different
journals and must have caused some confusion when one
journal strictly advocated the use of the statement while
others advised that it should only be consulted [21, 23].
A study conducted in 2013 examined the different evalua-
tions conducted since STARDwas introduced [22]. It showed
an overall improvement in the quality of the reporting of
diagnostic accuracy studies; nevertheless, the studies were
still hampered by lack of quality. The guidelines had been
followed bymany, but some of the very important items from
the list were still missing. Important items such as “blinding
of readers” and “methods for calculating test reproducibility”
were omitted, thus resulting in the possibility of biased
results. Notably, many researchers still did not apply the
flow diagram. Many of the studies included in the review
still recommended the use of STARD as it resulted in better
reporting. It is also worth remembering that many of these
studies were conducted shortly after the introduction of
STARD and therefore the implementation time has been
short. A recent report, which supports the above results,
compared studies conducted before, shortly after, and 10 years
after the implementation of STARD [24]. The main finding
was an overall increase of 3.4 reported items from the STARD
checklist from before the implementation compared with 10
years after. In contrast to previous evaluations of STARD, this
report also showed a significant increase in the use of the
International Scholarly Research Notices 5
flowchart. Moreover, this study suggested that some effort
should be put into the education of peer reviewers and journal
editors in order to endorse the use of STARD.
2.6. SPIRIT (http://www.spirit-statement.org/). SPIRIT (Stan-
dard Protocol Items: Recommendations for Interventional
Trials) was created in 2007 for the reporting of scientific trial
protocols [25]. The need for such a guideline was evident
through a systematic review, which found that many proto-
cols for randomized trials lacked information on important
components of the trial, such as primary outcome, treat-
ment allocation methods, and the use of blinding (masking)
[26]. It was examined that these shortcomings could lead
to inadequate reporting, poor trial conduct, and protocol
amendments.
In the development of SPIRIT, a team of trial investiga-
tors, healthcare professionals, methodologists, statisticians,
trial coordinators, journal editors, and representatives from
the research ethics community, industrial and nonindustrial
funders, and regulatory agencies worked together. They cre-
ated a statement that clarified the requirements for protocols
in clinical trials, that is, a list that included 33 items divided
into the following domains: administrative information,
introduction, methods, ethics and dissemination, and appen-
dices. Furthermore, it was advised that the protocol kept a
format, which included a table of contents, section headings,
glossary, and list of references. The format of SPIRIT has
incorporated some items and inspiration from CONSORT
in order to enable an easier transition from a SPIRIT-based
protocol to a final CONSORT-based report. It was hoped that
SPIRIT would promote transparency as well as an adequate
description of how the trial was planned. Furthermore, it
was hoped that, by improving the completeness of protocols,
queries to investigators about unclear information would
be reduced, thereby leading to an increase in efficiency. In
addition, it might ensure the requisite information for critical
appraisal and trial interpretation of the protocols.
SPIRIT helps to “lock” the protocol in conjunction with
mandatory registration at web domains such as https://
clinicaltrials.gov/ where studies have to be registered before
commencement to ensure transparency in the execution and
reporting of the study. By applying the SPIRIT statement to
“lock” the protocol, studies should not, for example, switch
endpoints so that a secondary endpoint is lifted to become
primary in the case where the primary outcome does not
meet the prespecified level of statistical significance.
3. Discussion
The publication of the CONSORT statement initiated a
cascade of changes in the reporting of medical research in
scientific journals. As outlined above, this has had great
impact on the quality of reporting of various types of medical
research. Specifically, it has been emphasized that changes
have to be made on how the guidelines are applied [23].
Still, the introduction of these various reporting guidelines
has not yet secured complete transparency and accurate
reporting, mainly because they are not followed as rigorously
as was intended. In particular, it is argued that neither journal
editors nor peer reviewers want to take full responsibility
for checking whether guidelines are adhered to. To attend
to this problem, academic employees at the editorial offices
of major journals need to secure that submitted manuscripts
adhere to the relevant guideline before they are sent to the
associate editors and to external peer review. This is costly
and will to some extent delay the review process but will
make manuscripts more suitable for publication should they
meet other relevant criteria for scientific merit. Another
way of securing adherence to reporting guidelines is the
instruction of the Committee on Publication Ethics (COPE)
Ethical Guidelines for Peer Reviewers [27] that sets forth
standards for peer reviewing ethics. The COPE guideline is
endorsed by major journals and sets out the basic principles
and standards to which peer reviewers should adhere during
the peer review process. Finally, predefined strategies for
updating and evaluating the various guidelines have not been
made. Ideally, guidelines should be rigorously evaluated and
updated regularly based on accumulated evidence.
Undoubtedly, there are barriers of communicating effi-
ciently the advantages and disadvantages of compliance to
guidelines. When reporting research findings, authors are
expected to make sure that the correct guideline is being
applied. On journals’ websites, which guideline they stipulate
and how they want them to be followed should be stated.This
varies greatly between journals [21, 23]. Furthermore, readers
of any kind have to familiarize themselves with the guideline
by which the article is written. In this regard, the EQUATOR
network offers some support through courses for authors,
reviewers, and editors [13]. However, it has been argued that
editors find it a practical burden and out of their competence
to check all submitted articles, and most editors do not want
to be the gatekeepers of the correct use of reporting guidelines
[23]. To this end, the obligation of adhering to publication
guidelines relies solely on the (group of) author(s).
So why do the reported findings still lack transparency
and accuracy with all these guidelines? Both the CONSORT
statement and an evaluating article state that the guide-
lines might encourage some authors to fabricate spurious
information in order to comply with the statement [2, 3].
Furthermore, authors might be limited to article word counts
and as a consequence feel the necessity to leave out important
items that fulfill the demands of the journal [28]. Certain
authors might be reluctant to comply with some guidelines,
as they feel deprived of their liberty in the research because
the study has to match perfectly the guideline assigned to
that type of study [23]. If this is the case, then the solution
for more transparent reporting might not be to follow the
guidelines more precisely but rather to find another way for
authors to apply guidelines, which would help them express
their message more clearly and not limit them.
Another implication of reporting guidelines is the miss-
ing reporting of research. Some research is currently not
being published because the application of the guidelines
makes it particularly apparent that a study has limitations
or does not conclude desired results [2]. If only articles that
adhere to reporting guidelines are published, a distorted
picture on the field will be created (publication bias). In
this instance, reporting guidelines constitute a barrier that
6 International Scholarly Research Notices
prevents inferior research from being published in high-
ranking journals and in turn from being cited (high-impact
journal articles cite primarily articles from the same or
other high-impact journals). However, many low- to middle-
impact journals allow publication of research articles that do
not adhere to reporting guidelines. In combination with the
open access strategy of many of these journals, this mitigates
the publication bias introduced by the inappropriate or
inefficient use of relevant guidelines.
4. Conclusion
The purpose of having reporting guidelines in medical
research is to create a manual for the authors to follow,
which should lead to total transparency, accurate reporting,
and easier assessment of the validity of reported research
findings. This goal has been reached to some degree, but it
is still necessary to be critical when appraising any research
article. It might be time for editors, authors, and reviewers to
assemble and figure out how to best use and recommend the
various reporting guidelines.
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